['neoplasms']
['rivaroxaban', 'placebo']

        Inclusion Criteria:

          -  Have histologically confirmed solid malignancy including but not limited to: pancreas,
             lung, stomach, colon, rectum, bladder, breast, ovary, renal or lymphoma (hematologic),
             with locally advanced or metastatic disease

          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2

          -  Have a Khorana thromboembolic risk Score greater than or equal to (>=) 2

          -  Creatinine clearance (CrCl) >= 30 milliliter per minute (mL/min)

          -  Plan to initiate systemic cancer therapy within plus or minus (+-) 1 week of receiving
             the first dose of study drug with the intention of receiving systemic cancer therapy
             during the double-blind treatment period for an intended duration determined by the
             treating oncologist according to standard protocols of clinical care

        Exclusion Criteria:

          -  Diagnosis of primary brain tumors

          -  Known history of brain metastases

          -  Bleeding diathesis, hemorrhagic lesions, active bleeding, and other conditions with a
             high risk for bleeding

          -  Hematologic malignancies with the exception of lymphoma

          -  Platelet count less than (<) 50,000/millimeter^3 (mm^3), Life expectancy of less than
             or equal to (<=) 6 months
      